Literature DB >> 33210114

Medicare Trends in Pathologist Participation, Service Utilization, and Payments.

Simone Arvisais-Anhalt1, Ellen Araj1, Jason Y Park1,2.   

Abstract

OBJECTIVES: Quantifying pathologist participation in Medicare services may be informative for the prediction of future workforce needs and reimbursement.
METHODS: A retrospective examination was performed of pathologist professional (Part B) Medicare billings and payments from 2012 to 2017. The Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use File was the primary data source.
RESULTS: From 2012 to 2017, there was an increase (3.7%; 11,215 up to 11,627) in pathologists providing Medicare Part B services. Female pathologists increased from 36.10% to 40.8% of pathologists during this time period. Normalized per pathologist, there was an increase (7.8%; 1,382 up to 1,489) in beneficiaries served as well as an increase (4.1%; 2,442 up to 2,543) in services performed. The top 10 pathology Part B services performed in a facility were all surgical pathology. Although services increased, the overall payment of Part B pathology services decreased (3%; $996,519,358 down to $966,615,856) during the study period.
CONCLUSIONS: Although there is increasing pathologist participation in Medicare, the workload per pathologist has increased. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Billing; Medicare; POSPUF; Part B; Pathology workforce; Payment

Mesh:

Year:  2021        PMID: 33210114     DOI: 10.1093/ajcp/aqaa167

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   5.400


  1 in total

1.  The Importance of Accurately Defining Gender and Sex in Pathology.

Authors:  Jeremy W Jacobs; Jacelyn E Peabody Lever; Yeonsoo S Lee; Katherine M Bryan; Garrett S Booth; Ihuoma O Njoku; Simone Arvisais-Anhalt; Ellen Araj; Jason Y Park
Journal:  Am J Clin Pathol       Date:  2022-07-01       Impact factor: 5.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.